Edition:
United Kingdom

Cesca Therapeutics Inc (KOOL.OQ)

KOOL.OQ on NASDAQ Stock Exchange Capital Market

0.40USD
20 Sep 2018
Change (% chg)

$0.01 (+2.56%)
Prev Close
$0.39
Open
$0.40
Day's High
$0.41
Day's Low
$0.39
Volume
18,726
Avg. Vol
129,346
52-wk High
$6.43
52-wk Low
$0.22

Latest Key Developments (Source: Significant Developments)

Cesca Therapeutics Inc Files for offering Of Up To 3.97 mln Shares Of Common Stock By Selling Stockholder
Wednesday, 19 Sep 2018 

Sept 19 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFER AND SALE BY SELLING STOCKHOLDER OF UP TO 3.97 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Cesca Therapeutics Announces Evaluation Agreement With The University Of North Carolina For X-Series Products
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS ANNOUNCES EVALUATION AGREEMENT WITH THE UNIVERSITY OF NORTH CAROLINA LINEBERGER ADVANCED CELLULAR THERAPEUTICS FACILITY FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING.CESCA THERAPEUTICS INC - CESCA WILL BE RESPONSIBLE FOR PROVIDING ITS X-SERIES PRODUCTS, ALONG WITH REQUIRED TRAINING AND SUPPORT.  Full Article

Cesca Therapeutics Announces First Evaluation Agreement With A Leading U.S. Academic Research Institution For X-Series Products
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS ANNOUNCES FIRST EVALUATION AGREEMENT WITH A LEADING U.S. ACADEMIC RESEARCH INSTITUTION FOR X-SERIES™ PRODUCTS THAT PROVIDE AUTOMATED, CLOSED SYSTEM CELLULAR PROCESSING.CESCA THERAPEUTICS INC - CESCA WILL BE RESPONSIBLE FOR PROVIDING ITS X-SERIES PRODUCTS, ALONG WITH REQUIRED TRAINING AND SUPPORT.  Full Article

Cesca Subsidiary Expands Into CAR-T Related Contract Development And Manufacturing
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Cesca Therapeutics Inc ::CESCA’S DEVICE SUBSIDIARY, THERMOGENESIS, EXPANDS INTO CAR-T RELATED CONTRACT DEVELOPMENT AND MANUFACTURING (CDMO) SERVICES.CESCA THERAPEUTICS - UNIT SIGNED LICENSE AGREEMENT WITH INCOCELL TIANJIN, A UNIT OF BOYALIFE GROUP.CESCA THERAPEUTICS - UNIT GRANTED INCOCELL LICENSE TO BUY, AT DISCOUNTED PRICE, CERTAIN DEVICES, CONSUMABLES, KITS IN CERTAIN ASIA PACIFIC COUNTRIES.CESCA THERAPEUTICS- TERRITORIES COVERED UNDER AGREEMENT ARE CHINA, JAPAN, SOUTH KOREA, TAIWAN, HONG KONG, MACAU, SINGAPORE, MALAYSIA, INDONESIA, INDIA.CESCA THERAPEUTICS INC - UNIT ENTITLED TO PERCENTAGE OF INCOCELL'S GROSS CONTRACT DEVELOPMENT REVENUES.  Full Article

Cesca Therapeutics Announces Pricing Of Public Offering
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 900,000 SHARES OF COMMON STOCK.CESCA THERAPEUTICS INC - PRICED REGISTERED PUBLIC OFFERING AT $3.00 PER SHARE​.  Full Article

Cesca Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cesca Therapeutics Inc ::CESCA THERAPEUTICS INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Cesca Therapeutics reports quarterly loss per share $0.24
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Cesca Therapeutics Inc ::Cesca Therapeutics announces financial results for the three months ended September 30, 2017 and provides corporate update.Quarterly loss per share $0.24.Quarterly revenue $3.1 million versus $3.8 million.  Full Article

BRIEF-Cesca Therapeutics Says Offering Up To 3.2 Million Units

* CESCA THERAPEUTICS SAYS OFFERING UP TO 3.2 MILLION UNITS, EACH UNIT CONSISTING OF 1 SHARE OF COMMON STOCK, ONE COMMON WARRANT TO PURCHASE 1 SHARE OF STOCK Source text: (https://bit.ly/2I8M01T) Further company coverage: